Abstract:Background : Tripterygium wilfordii has been widely used for the treatment of rheumatoid arthritis, which is frequently accompanied by severe gastrointestinal damage. The molecular mechanism underlying the gastrointestinal injury of Tripterygium wilfordii are yet to be elucidated. Methods : Transmission electron microscope assay, pathological and biochemical analysis were applied to identify intestinal bleeding. Metabolic changes in the serum and intestine were determined by metabolomics. In vivo (time-dependent effect and dose-response) and in vitro (double luciferase reporter gene system, DRATs, molecular docking, HepG2 cells and small intestinal organoids) studies were used to identify the inhibition role of celastrol on intestinal FXR. Fxr -knockout mice and inhibitors or agonists of FXR were used to evaluate the role of FXR in the intestinal bleeding induced by Tripterygium wilfordii . Results : The present study shown that co-treatment with triptolide + celastrol (from Tripterygium wilfordii ) could induce intestinal bleeding in mice. Metabolomic analysis indicated that celastrol suppressed intestinal FXR signaling, and further molecular studies identified that celastrol expected to be a novel intestinal FXR inhibitor. In Fxr -knockout mice or the wild type mice pre-treated with pharmacological inhibitors of FXR, triptolide alone could activate the duodenal JNK pathway and induce intestinal bleeding, which recapitulated the pathogenic features by co-treatment with triptolide and celastrol. Lastly, intestinal bleeding induced by co-treatment with triptolide and celastrol could be effectively attenuated by the FXR or gut-restricted FXR agonist through downregulation of duodenal JNK pathway. Conclusions : The synergistic effect between triptolide and celastrol contributed to the gastrointestinal injury induced by Tripterygium wilfordii via dysregulation of the FXR-JNK axis, which hinted that celastrol should be included in the quality marker system of Tripterygium wilfordii preparation. Determining the mechanism of FXR-JNK axis in intestinal bleeding was expected to become an additional therapeutic target for the treatment of gastrointestinal hemorrhage diseases. This study provides a new idea for the quality standard system of Tripterygium wilfordii and the treatment of gastrointestinal injury.

Dissection of Targeting Molecular Mechanisms of Celastrol-induced Nephrotoxicity via A Combined Deconvolution Strategy of Chemoproteomics and Metabolomics

Celastrol ameliorates cisplatin nephrotoxicity by inhibiting NF-κB and improving mitochondrial function

Celastrol Induces DNA Damage and Cell Death in BCR-ABL T315I-mutant CML by Targeting YY1 and HMCES

Celastrol: An Update on Its Hepatoprotective Properties and the Linked Molecular Mechanisms

Quantitative chemical proteomics reveals anti-cancer targets of Celastrol in HCT116 human colon cancer cells

Celastrol attenuates renal injury in 5/6 nephrectomized rats via inhibiting epithelial-mesenchymal transition and transforming growth factor-β1/Smad3 pathway

Celastrol pretreatment attenuates concanavalin A-induced hepatitis in mice by suppressing interleukin-6/STAT3-interleukin-17 signaling

Mechanistic engineering of celastrol liposomes induces ferroptosis and apoptosis by directly targeting VDAC2 in hepatocellular carcinoma

ER Stress-Mediated Apoptosis Induced by Celastrol in Cancer Cells and Important Role of Glycogen Synthase Kinase-3Β in the Signal Network

Celastrol induces ferroptosis in activated HSCs to ameliorate hepatic fibrosis via targeting peroxiredoxins and HO-1

Metabolomics profiles delineate uridine deficiency contributes to mitochondria-mediated apoptosis induced by celastrol in human acute promyelocytic leukemia cells

Targeting OPA1-Mediated Mitochondrial Fusion Contributed to Celastrol's Anti-Tumor Angiogenesis Effect

Exploration of the effect of Celastrol on protein targets in nasopharyngeal carcinoma: Network pharmacology, molecular docking and experimental evaluations

Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies

Research Progress in Pharmacologic Molecular Targets of Celastrol

Integrating Network Pharmacology with in vitro Experiments to Validate the Efficacy of Celastrol Against Hepatocellular Carcinoma Through Ferroptosis

Celastrol ameliorates acute liver injury through modulation of PPARα

The anti-cancer mechanism of Celastrol by targeting JAK2/STAT3 signaling pathway in gastric and ovarian cancer

The Protective Role of Celastrol in Renal Ischemia-Reperfusion Injury by Activating Nrf2/HO-1, PI3K/AKT Signaling Pathways, Modulating NF-κb Signaling Pathways, and Inhibiting ERK Phosphorylation

A comprehensive study of celastrol metabolism in vivo and in vitro using ultra‐high‐performance liquid chromatography coupled with hybrid triple quadrupole time‐of‐flight mass spectrometry

Celastrol as an intestinal FXR inhibitor triggers tripolide-induced intestinal bleeding: Underlying mechanism of gastrointestinal injury induced by Tripterygium wilfordii